太平洋给予普洛药业买入评级：Q2利润阶段性承压，CDMO业务毛利贡献创新高

Group 1 - The core viewpoint of the report is that Pacific Securities has given a "buy" rating for Pro Pharmaceutical (000739.SZ) based on several positive indicators [2] - Q2 revenue and profit faced pressure, but gross margin showed significant improvement [2] - The CDMO (Contract Development and Manufacturing Organization) business is gradually entering a harvest period, with gross margin contribution surpassing that of the API (Active Pharmaceutical Ingredient) business for the first time [2] - The stock buyback reflects the company's confidence in its long-term development [2]